Hoth Therapeutics, Inc. Made Headway

Tue, Jan 07, 2025 at 07:12 PM

Hoth Therapeutics, Inc. (HOTH:NASDAQ) rocketted at $2.28, a gain of 178.2%. On Tue, Jan 07, 2025, HOTH:NASDAQ hit a New 2-Week High of $2.28. The stock got featured on our News Catalysts scanner on Tue, Jan 07, 2025 at 03:10 PM in the 'BIOTECH' category. From Tue, Dec 24, 2024, the stock recorded 50.00% Up Days and 44.44% Green Days

The stock spiked on Tue, Jan 07, 2025 at $3.8 with a volume of 415M+.

About Hoth Therapeutics, Inc. (HOTH:NASDAQ)

Hoth Therapeutics Inc is a development stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Top 10 Gainers:

DatChat Inc. (DATS:NASDAQ), 355.61%
Hoth Therapeutics, Inc. (HOTH:NASDAQ), 178.18%
DarioHealth Corp. (DRIO:NASDAQ), 84.96%
SRIVARU Holding Limited (SVMH:NASDAQ), 81.43%
Healthy Choice Wellness Corp. Class A (HCWC:NYSEMKT), 64.78%
SPI Energy Co., Ltd. (SPI:NASDAQ), 58.14%
Algorhythm Holdings Inc Com Par $0.01 (RIME:NASDAQ), 56.77%
Syra Health Corp. (SYRA:NASDAQ), 50.7%
SRAX, Inc. (SRAX:NASDAQ), 50%
Sol-Gel Technologies Ltd. (SLGL:NASDAQ), 40.03%